Celcuity

Scientific Posters & Publications

Drug development backed by sound research

Below are a sample of innovative research published and presented by our team and our collaborators.

Filter by Cancer Type:

2024
Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions

Stefano Rossetti, Aaron Broege, Jhomary Molden, Ross Kopher, Stephen Schulz, Ky McCracken, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2024 San Antonio Breast Cancer Symposium (SABCS)
2024
Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models

Stefano Rossetti, Aaron Broege, Megan Seibel, Jhomary Molden, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2024 San Antonio Breast Cancer Symposium (SABCS)
2024
Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib

Aaron Broege, Stefano Rossetti, Adrish Sen, Aurul Menon, Ian MacNeil, Jhomary Molden, and Lance Laing

Cancers
2024
Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway

Adrish Sen, Salmaan Khan, Stefano Rossetti , Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz and Lance Laing

Molecular Oncology
2024
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study

Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, E Claire Dees, Peter Kabos, Samuel Suzuki, Sarah C Mutka, Brian F Sullivan, Igor Gorbatchevsky, Robert Wesolowski

The Lancet Oncology
2023
Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency & efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models

Stefano Rossetti, Aaron Broege, Adrish Sen, Salmaan Khan, Ian MacNeil, Jhomary Molden, Igor Gorbatchevsky, Brian Sullivan, Lance Laing

2023 San Antonio Breast Cancer Symposium (SABCS)
2023
Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment naïve patients

Hope S. Rugo, Robert Wesolowski, Erica M. Stringer Reasor, Hyo Han, Jennifer M. Specht, E. Claire Dees, Peter Kabos, Ulka Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander Spira, Anne F. Schott, Maysa Abu Khalaf, Sarah C. Mutka, Samuel Suzuki, Igor Gorbatchevsky, Rachel M. Layman

2023 ESMO Breast Cancer Annual Congress
2023
Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on gynecological cancer models regardless of their PI3K pathway mutational status

Stefano Rossetti, Aaron Broege, Ian MacNeil, Ben Rich, Jhomary Molden, Brian Sullivan, Lance Laing

2023 American Association for Cancer Research
2023
A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara Hurvitz, Fabrice Andre, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo Han, Miguel Martin, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl

2023 American Association for Cancer Research
2023
Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models differing in PI3K or PTEN mutational status

Adrish Sen, Salmaan A. Khan, Ian A. MacNeil, Benjamin E. Rich, Jhomary S. Molden, Laura N. Davis, Stefano Rossetti, Aaron M. Broege, Lance G. Laing

2023 ASCO Genitourinary (GU) Cancers Symposium
2022
A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)

Sara Hurvitz, Fabrice Andre, Massimo Cristofanilli, Giuseppe Curigliano, Antonio Giordano, Hyo Han, Miguel Martin, Barbara Pistilli, Hope Rugo, Robert Wesolowski, Samuel Suzuki, Sarah C. Mutka, Igor Gorbatchevsky, Sibylle Loibl

2022 San Antonio Breast Cancer Symposium (SABCS)
2022
Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status

Robert Wesolowski, Hope S. Rugo, Erica M. Stringer-Reasor, Hyo Han, Jennifer M. Specht, E. Claire Dees, Peter Kabos, Ulka Vaishampayan, Seth A. Wander, Janice Lu, Keerthi Gogineni, Alexander Spira, Anne F. Schott, Maysa Abu-Khalaf, Pratima Nayak, Brian F. Sullivan, Igor Gorbatchevsky, Rachel M. Layman

2022 San Antonio Breast Cancer Symposium (SABCS)
2022
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer 2022

Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca S. Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka & Zev A. Wainberg

British Journal of Cancer
2022
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy. Cell Communication and Signaling, 20:4, 2022

Ian A. MacNeil, Salmaan A. Khan, Adrish Sen, Sajjad M. Soltani, David J. Burns, Brian F. Sullivan & Lance G. Laing

CELSignia
2021
Phase II study of trastuzumab biosimilar (Herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy: KM-10A (KCSG BR 18-13) interim analysis

Ju Won Kim, Hee Kyung Ahn, Jong Gwon Choi, Yee Soo Chae, Gyeong-Won Lee, KeonUk Park, Eunmi Lee, Sung Hoon Sim, Jee Hyun Kim, Yeon Hee Park, Miso Ki1, Jin Hyun Park, Jeong Eun Kim, Han Jo Kim, Mi Sun Ahn, So Yeon Oh, Min Hwan Kim, Su-Jin Koh, Kyoung Eun Lee, Myoung Joo Kang, Jae Ho Byun, Joo young Ha, Jung Hye Kwon, Joo Young Jung, Su Ee Lee, Inhae Park, and Kyong Hwa Park

2021 San Antonio Breast Cancer Symposium (SABCS)